All Oncology News

Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

The Chinese NMPA has approved sacituzumab tirumotecan for EGFR-mutant advanced NSCLC following progression on an EGFR TKI and chemotherapy.

China’s NMPA has accepted an MAA seeking the approval of foritinib for ALK-positive advanced non–small cell lung cancer.

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in ccRCC.

Lower odds of enrollment in cancer clinical trials could be associated with education, transportation, and neighborhood resources.

Zongertinib showed responses across HER2-mutated tumor types, including in lung cancer, with a tolerable safety profile.

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

Megan Melody, MD, discusses her journey as an oncologist and the importance of mentorship and a supportive work environment to empower women in the field.

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.

PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.

A post hoc analysis of the NATALEE trial suggests that ribociclib dose reduction preserves iDFS in hormone receptor+/HER2-negative early breast cancer.

Perioperative durvalumab plus FLOT improved event-free survival in resectable gastric or gastroesophageal junction cancer.

Nivolumab plus ipilimumab was approved by the European Commission for first-line, unresectable or advanced HCC.

Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.

Researchers at Fox Chase Cancer Center published 2 reviews on the role of AKT, also known as protein kinase B, in the development and treatment of cancer.

Treatment with liso-cel induced long-term CR/CRi rates and high uMRD rates in patients with CLL/SLL following progression on BTK inhibition and venetoclax.